摘要
目的探讨注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合甲氨蝶呤治疗类风湿关节炎的临床效果。方法选取2017年1月至2018年12月西安市第五医院收治的136例类风湿关节炎患者作为研究对象,按照随机数字表法将其分为试验组与对照组,各68例。两组患者均采用醋氯芬酸进行常规治疗,在此基础上,对照组采用甲氨蝶呤+硫酸羟氯喹治疗,试验组采用甲氨蝶呤+注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗。比较两组患者治疗3、6个月后的治疗总有效率、治疗前、后的机体关节症状严重程度、血清相关细胞因子水平及不良反应发生情况。结果治疗3、6个月后,试验组的治疗总有效率均显著高于对照组(P<0.05)。治疗后,两组的DAS28评分均显著降低,且试验组低于对照组(P<0.05)。治疗后,两组的血清COX-2、TNF-α、IL-6、M-CSF水平均降低,且试验组低于对照组(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合甲氨蝶呤治疗类风湿关节炎临床效果显著,可加快关节症状改善,减轻机体炎性反应,促进患者恢复,且可有效保证治疗安全性。
Objective To investigate the clinical effect of recombinant human typeⅡtumor necrosis factor receptor-antibody fusion protein for injection combined with methotrexate in the treatment of rheumatoid arthritis.Methods From January 2017 to December 2018,136 patients with rheumatoid arthritis admitted in Xi'an No.5 hospital were selected as the study objects.According to the random number table method,the patients were divided into experimental group and control group,with 68 cases in each group.Both groups were treated with aceclofenac,on this basis,the control group was treated with methotrexate+hydroxychloroquine sulfate,the experimental group was treated with methotrexate+recombinant human typeⅡtumor necrosis factor receptor-antibody fusion protein for injection.The total effective rate of treatment after 3 and 6 months of treatment,the severity of the body joint symptoms,the level of serum related cytokines before and after treatment and the occurrence of adverse reactions were compared between the two groups.Results After 3 and 6 months of treatment,the total effective rate of treatment in the experimental group were significantly higher than those in the control group(P<0.05).After treatment,the score of DAS28 in the two groups decreased significantly,and that in the experimental group was lower than the control group(P<0.05).After treatment,the levels of serum COX-2,TNF-α,IL-6 and M-CSF in the two groups decreased,and those in the experimental group were lower than the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Recombinant human typeⅡtumor necrosis factor receptor-antibody fusion protein for injection combined with methotrexate has a significant clinical effect in the treatment of rheumatoid arthritis,which can accelerate the improvement of joint symptoms,reduce the inflammatory response of the body,promote the recovery of patients,and effectively ensure the safety of treatment.
作者
刘昌莲
华莎
李晓明
王丽娜
LIU Chang-lian;HUA Sha;LI Xiao-ming;WANG Li-na(Rheumatology Immunology Department,Xi'an No.5 Hospital,Xi'an 710082,China)
出处
《临床医学研究与实践》
2020年第11期24-26,共3页
Clinical Research and Practice
关键词
注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白
甲氨蝶呤
类风湿关节炎
recombinant human typeⅡtumor necrosis factor receptor-antibody fusion protein for injection
methotrexate
rheumatoid arthritis
